The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine.
S L Cappendijk, D Fekkes, M R Dzoljic
Behavioural brain research November 16, 1994 DOI: 10.1016/0166-4328(94)90080-9 via PubMed
Summary
AI-generated from the abstractIn morphine-dependent rats, norharman (20 mg/kg) and ibogaine (40 mg/kg) each reduced the severity of withdrawal symptoms triggered by naloxone (4 mg/kg). Specific signs including teeth-chattering, chewing, penile licking, and diarrhea were lessened by both compounds. Norharman additionally decreased withdrawal-related grooming and rearing. The findings suggest that both norharman and ibogaine can inhibit opioid withdrawal syndrome.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Morphine-dependent rats |
| Interventions | Norharman Ibogaine |
| Dose | 20 mg/kg norharman, 40 mg/kg ibogaine, 4 mg/kg naloxone |
| Citations | 57 |
| Key finding | Norharman and ibogaine each attenuated naloxone-precipitated withdrawal syndrome in morphine-dependent rats. |
Abstract
Norharman (20 mg/kg, i.p.) and ibogaine (40 mg/kg, i.p.) significantly attenuated naloxone (4 mg/kg, i.p.)-precipitated withdrawal syndrome in morphine-dependent rats. Several withdrawal signs, such as teeth-chattering, chewing, penile licking and diarrhoea, were decreased by both norharman and ibogaine. In addition, norharman reduced also the withdrawal grooming and rearing. It is concluded that both norharman and ibogaine are inhibitors of withdrawal syndrome in morphine-dependent rats.